690635-44-0Relevant academic research and scientific papers
Identification through structure-based methods of a bacterial NAD +-dependent DNA ligase inhibitor that avoids known resistance mutations
Murphy-Benenato, Kerry,Wang, Hongming,McGuire, Helen M.,Davis, Hajnalka E.,Gao, Ning,Prince, D. Bryan,Jahic, Haris,Stokes, Suzanne S.,Boriack-Sjodin, P. Ann
, p. 360 - 366 (2014)
In an attempt to identify novel inhibitors of NAD+-dependent DNA ligase (LigA) that are not affected by a known resistance mutation in the adenosine binding pocket, a detailed analysis of the binding sites of a variety of bacterial ligases was
Identification through structure-based methods of a bacterial NAD+-dependent DNA ligase inhibitor that avoids known resistance mutations
Murphy-Benenato, Kerry,Wang, Hongming,McGuire, Helen M.,Davis, Hajnalka E.,Gao, Ning,Prince, D. Bryan,Jahic, Haris,Stokes, Suzanne S.,Boriack-Sjodin, P. Ann
supporting information, p. 360 - 366 (2015/09/08)
In an attempt to identify novel inhibitors of NAD+-dependent DNA ligase (LigA) that are not affected by a known resistance mutation in the adenosine binding pocket, a detailed analysis of the binding sites of a variety of bacterial ligases was
Antiinflammation agents
-
Page/Page column 18; 25-26, (2010/02/06)
Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic, infectious and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism, infection and cell proliferation. The subject compounds contain a fused heterobicyclic ring.
